Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088888 · ClinicalTrials.gov registry record · Phase 1
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
A Phase 1 study of Chronic Myelogenous Leukemia, sponsored by Shenzhen TargetRx Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 2
- Study locations
NCT06088888: Recruiting Phase 1 study of Chronic Myelogenous Leukemia, sponsored by Shenzhen TargetRx Co..
NCT06088888 is a Phase 1 study of Chronic Myelogenous Leukemia that is actively recruiting participants, run by Shenzhen TargetRx Co.. The registered enrollment target is 90 participants, below the 280-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06088888, a Phase 1 study of Chronic Myelogenous Leukemia, is actively recruiting participants, sponsored by Shenzhen TargetRx Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Primary Outcome
To determine the RDE of TGRX-678 in CML patients to be applied in Cohort Expansion part of the study
Conditions Studied
Interventions
- DRUG TGRX-678
Study Locations (2)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT06088888 shows while recruiting
NCT06088888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 280-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which TGRX-678 is the first listed.
NCT06088888 reports a single indexed study location in Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT06088888 about?
NCT06088888 is a clinical study titled "TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia". The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
What is the current status of trial NCT06088888?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-07-02. Estimated completion is 2027-06-30.
What conditions does trial NCT06088888 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT06088888?
The interventions under investigation include: TGRX-678 (DRUG).
Who is sponsoring clinical trial NCT06088888?
This trial is sponsored by Shenzhen TargetRx Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088888 being conducted?
This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06088888's enrollment target sits among peer trials
90 12th of 29 higher than 18 of 29 other Chronic Myelogenous Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelogenous Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
-
Administration of Donor T Cells With the Caspase-9 Suicide Gene
ACTIVE NOT RECRUITING · Phase 1
-
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
COMPLETED · Phase 1
-
Improving Blood Stem Cell Collection and Transplant Procedures
COMPLETED · Phase 1
-
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
COMPLETED · Phase 1
-
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI